MARLBOROUGH, Mass. / Jul 09, 2024 / Business Wire / Millions of women in the United States have missed screenings for serious, often life-threatening conditions, according to a new survey released today by women’s health innovator Hologic, Inc. (Nasdaq: HOLX).
The nationally representative study, commissioned by Hologic and conducted by Gallup, reveals a vast “Screening Action Gap.” Although women overwhelmingly say regular health screenings are important, an estimated 72 million have skipped or delayed a recommended screening. These missed screenings include those for significant health conditions like breast, cervical and colorectal cancers, which together kill more than 70,000 U.S. women each year.
The survey asked 4,001 women about their experiences and perspectives on health. It builds on the annual Hologic Global Women’s Health Index, which captures the views of women and girls from more than 140 countries.
“We choose to put energy and resources behind the Global Women’s Health Index because you can only improve what’s measured,” said Stephen P. MacMillan, Chairman, President and CEO of Hologic. “This survey, our first-ever focused on the U.S., reveals so much about the challenges women face when prioritizing their health. It’s sobering to think that 72 million American women miss life-changing screenings because of cost, anxiety and prior negative experiences. Our hope is that this survey will be the impetus for more screening awareness, education and policy.”
Key findings of the U.S. survey include:
To see the full survey and related resources, visit WomensHealthIndex.com/Hologic-US-Health-Survey.
About Hologic, Inc.
Hologic, Inc. is a global medical technology innovator focused on improving the health and well-being of women, their families and communities through early detection and treatment. Its advancements include invention of the world’s first commercial 3D mammography system to find breast cancer earlier; leadership in testing for cervical cancer, sexually transmitted infections and respiratory illnesses; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding. The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data framework for improving women’s well-being.
For more information about the company, visit www.Hologic.com.
Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
About Gallup
Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.
Last Trade: | US$71.65 |
Daily Change: | 0.89 1.26 |
Daily Volume: | 7,640,910 |
Market Cap: | US$16.260B |
December 18, 2024 December 09, 2024 December 02, 2024 November 04, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB